High-dose chemotherapy followed by autologous stem cell transplantation for metastatic rhabdomyosarcoma--a systematic review.

Frank Peinemann; Nicolaus Kröger; Carmen Bartel; Ulrich Grouven; Max Pittler; Rudolf Erttmann; Michael Kulig

doi:10.1371/journal.pone.0017127

High-dose chemotherapy followed by autologous stem cell transplantation for metastatic rhabdomyosarcoma--a systematic review.

Frank Peinemann
Nicolaus Kröger
Carmen Bartel
Ulrich Grouven
Max Pittler
Rudolf Erttmann
Michael Kulig

Related Research units

Department of Stem Cell Transplantation
Department of Pediatric Hematology and Oncology

Abstract

Patients with metastatic rhabdomyosarcoma (RMS) have a poor prognosis. The aim of this systematic review is to investigate whether high-dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (HSCT) in patients with metastatic RMS has additional benefit or harm compared to standard chemotherapy.

Bibliographical data

Original language	English
Article number	2
ISSN	1932-6203
DOIs	https://doi.org/10.1371/journal.pone.0017127
Publication status	Published - 2011

pubmed	21373200